Psychopharmacological Drugs Advisory Committee
February 15, 2001
Briefing Information
NDA 20-919: Zeldox (ziprasidone mesylate IM, Pfizer.)
Pfizer Global Research & Development
Disclaimer
The statements contained in this document are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
Pfizer July 19, 2000 submission
Food and Drug Administration